



GENOTYPIC HIV-1 RESISTANCE PROFILE

SAMPLE1



DRUG RESISTANCE INTERPRETATION

1) Resistance to Reverse transcriptase Inhibitors (RTI)

Resistance to Nucleoside / Nucleotide RTI (NRTI)

Abacavir (ABC)	High-Level Resistance	T215I 98.44, K219E 98.87, D67T 91.69, T69Insertion 96.97
Zidovudine (AZT)	High-Level Resistance	T215I 98.44, K219E 98.87, D67T 91.69, T69Insertion 96.97
Stavudine (D4T)	High-Level Resistance	T215I 98.44, K219E 98.87, D67T 91.69, T69Insertion 96.97
Didanosine (DDI)	High-Level Resistance	T215I 98.44, K219E 98.87, D67T 91.69, T69Insertion 96.97
Emtricitabine (FTC)	Intermediate Resistance	T69Insertion 96.97
Lamivudine (LMV)	Intermediate Resistance	T69Insertion 96.97
Tenofovir disoproxil fumarate (TDF)	High-Level Resistance	T215I 98.44, K219E 98.87, D67T 91.69, T69Insertion 96.97

Drug Resistance Associated Mutations

Resistance to Non-Nucleoside RTI (NNRTI)

Doravirine (DOR)	High-Level Resistance	V108I 98.22, P225H 98.68, A98G 97.87
Efavirenz (EFV)	High-Level Resistance	V108I 98.22, G190A 97.91, P225H 98.68, A98G 97.87
Etravirine (ETR)	Low-Level Resistance	G190A 97.91, A98G 97.87
Nevirapine (NVP)	High-Level Resistance	V108I 98.22, G190A 97.91, P225H 98.68, A98G 97.87
Rilpivirine (RPV)	Intermediate Resistance	G190A 97.91, A98G 97.87

2) Resistance to Protease Inhibitors (PI)

Atazanavir (ATV)	Susceptible
Darunavir (DRV)	Susceptible
Fosamprenavir (FPV)	Susceptible
Indinavir (IDV)	Susceptible
Lopinavir (LPV)	Susceptible
Nelfinavir (NFV)	Susceptible
Saquinavir (SQV)	Susceptible
Tipranavir (TPV)	Susceptible

3) Resistance to Integrase inhibitors (II)

Integrase mutations not detected